Rapport Therapeutics Reports Strong Q1, Secures $20M Collaboration, Extends Cash Runway to H2 2029

summarizeSummary

Rapport Therapeutics announced strong Q1 2026 results, including new collaboration revenue and an extended cash runway into H2 2029, alongside accelerated timelines for its bipolar mania clinical trial.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported a net loss of $19.9 million for Q1 2026, an improvement from $24.1 million in Q1 2025, and recognized $20.0 million in collaboration revenue from the Tenacia License Agreement.

• Extended Cash Runway

  Cash, cash equivalents, and short-term investments totaled $476.8 million as of March 31, 2026, providing sufficient funding for operating expenses and capital expenditure requirements into the second half of 2029.

• Accelerated Bipolar Mania Trial Timeline

  Topline results for the Phase 2 proof-of-concept trial in bipolar mania are now expected in Q4 2026, ahead of the previously guided first half of 2027.

• Advancing Clinical Pipeline

  Phase 3 program for RAP-219 in focal onset seizures is on track to initiate in Q2 2026, and IND-enabling activities have begun for RAP-641, an alpha6beta4 nAChR agonist for chronic pain and migraine.

auto_awesomeAnalysis

Rapport Therapeutics reported a significantly improved net loss of $19.9 million for Q1 2026, compared to $24.1 million in Q1 2025, driven by a new $20.0 million collaboration revenue from Tenacia Biotechnology. The company's cash, cash equivalents, and short-term investments stand at a robust $476.8 million, extending its operational runway into the second half of 2029. Clinical development is progressing with Phase 3 trials for RAP-219 in focal onset seizures on track for Q2 2026, and topline results for the bipolar mania Phase 2 trial now expected in Q4 2026, ahead of previous guidance. The CEO also adopted a routine 10b5-1 plan for future share sales.